AGP
KNSA icon

Artia Global Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Artia Global Partners’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.41M Hold
29,200
– – 0.28% 41
2025
Q4 		$1.2M Hold
29,200
– – 0.17% 47
2025
Q3 		$1.13M Hold
29,200
– – 0.18% 42
2025
Q2 		$808K Buy
+29,200
New +$743K 0.19% 33

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Artia Global Partners's KNSA Position: Q1 2026 in Review

Artia Global Partners held its Kiniksa Pharmaceuticals (KNSA) position steady in Q1 2026 at 29,200 shares worth $1.41M. The position accounts for 0.28% of the portfolio, ranked #41.

Artia Global Partners first reported a position in KNSA in Q2 2025 and has held it in 4 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Artia Global Partners held 29,200 shares of Kiniksa Pharmaceuticals worth $1.41M as of Q1 2026.
  • Artia Global Partners left its Kiniksa Pharmaceuticals share count unchanged in Q1 2026.
  • Kiniksa Pharmaceuticals made up 0.28% of Artia Global Partners's portfolio in Q1 2026, its #41 holding.
  • Artia Global Partners first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Artia Global Partners's 13F filing for Q1 2026, filed 15 May 2026.